SIGNing a symbiotic treaty with gut microbiota. (3rd March 2015)

• Record Type: Journal Article
• Authors: Lugo‐Villarino, Geanncarlo; Neyrolles, Olivier
• Is Part Of: EMBO journal. Volume 34:Number 7(2015)
• Page Start: 829
• Page End: 831
• Publication Date: 2015-03-03
• Subjects: Molecular biology -- Periodicals; 572.805
• DOI: 10.15252/embj.201591266
• Languages: English
• ISSNs: 0261-4189

Abstract

<abstract abstract-type="main" id="embj201591266-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p content-type="executiveSummary">Beneficial microbes hold great promise for the treatment of a wide range of immune and inflammatory disorders. In this issue of <italic>The EMBO Journal</italic>, Lightfoot and colleagues report how the food‐grade bacterium <italic>Lactobacillus acidophilus</italic> helps the immune system to limit experimental colitis in mice through interaction between SIGNR3 and surface layer protein A (SlpA) in <italic>L. acidophilus</italic>. These results pave the way for future development of novel therapies for inflammatory diseases, including inflammatory bowel disease.</p> </abstract>